Settled, paying · closes November 9, 2026
Generic drug price-fixing MDL, the $533 million settlement and who can claim
Last checked July 21, 2026
In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724) has been running in the U.S. District Court for the Eastern District of Pennsylvania for about a decade, in front of Judge Cynthia M. Rufe. The end-payer class accuses generic manufacturers of agreeing among themselves to raise prices, rig bids and divide up customers.
Four defendants have settled with the end-payer class for a combined $533 million. Claims are open now and close November 9, 2026. You need receipts or similar records to file.
The allegations
The plaintiffs say competitors coordinated on pricing for roughly 200 generic medications sold between May 1, 2009 and December 31, 2019. The list includes albuterol, amitriptyline, baclofen, celecoxib, doxycycline, fluoxetine, gabapentin, levothyroxine, pravastatin and propranolol, among others.
The settling defendants are Sandoz Inc. and Fougera Pharmaceuticals ($275 million), Sun Pharmaceutical Industries and Taro Pharmaceuticals ($200 million), Heritage Pharmaceuticals ($29 million) and Apotex Corp. ($29 million). All four deny liability.
Who the end-payer class includes
- Individual consumers, businesses, union health plans and other third-party payers who paid out of pocket for at least one covered generic during the class period.
- Purchases made in any U.S. state except Indiana and Ohio, or in Washington D.C., Puerto Rico or the U.S. Virgin Islands.
- The payment must have been a copay, deductible or full cash price. Prescriptions fully covered by insurance with nothing paid by you do not count.
- Federal government entities, state Medicaid agencies, pharmacy benefit managers and fully insured employers are excluded.
Where the litigation stands
The larger MDL continues against other manufacturers. This claim process covers only the four settlements above. The court has approved the notice program, and the administrator is accepting claims through November 9, 2026, online or by paper form.
Payments are pro rata. Each approved claimant's share is tied to documented spending on covered drugs, so larger copay totals mean a larger share.
Filing with the administrator
Intake runs through genericdrugsendpayersettlement.com. Before you start, pull pharmacy receipts, insurer explanation-of-benefits statements or pharmacy printouts that show the drug name and what you paid. Upload those with the online form, or mail a paper form from the site.
After submission, the administrator checks each claim and may ask for more documents. Payments follow final court approval of the distribution plan. Filing is free on the administrator's site; Payout lists this case as a free, optional way to track it.
Questions about the Generic Drug Price-Fixing case
Is proof of purchase required for the generic drug settlement?
Yes. Your share is calculated from documented spending, so you need pharmacy receipts, insurer EOB statements or similar records showing the drug and the amount you paid.
Which court is handling MDL 2724?
The U.S. District Court for the Eastern District of Pennsylvania, with Judge Cynthia M. Rufe presiding.
Why are Indiana and Ohio excluded?
The end-payer class definition covers every state except those two, plus D.C., Puerto Rico and the U.S. Virgin Islands. The settlement documents set that boundary; the administrator applies it.
Is the whole generic drug case over?
No. Only four defendant groups have settled with the end-payer class. Claims against other manufacturers in the MDL continue.
There are more like this open right now
Payout tracks the whole docket and files the settled ones you qualify for. Free.